Cover Image
市場調查報告書

腺苷酸A3受體 (ADORA3) - 開發中產品分析

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 358700
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
腺苷酸A3受體 (ADORA3) - 開發中產品分析 Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018
出版日期: 2018年03月13日 內容資訊: 英文 71 Pages
簡介

腺苷酸A3受體,又被稱之為ADORA3,是腺苷酸受體。腺苷酸A3受體可在心缺血的時候持續性介入心臟保護功能,是G蛋白偶聯受體 (GPCR) 。

本報告提供腺苷酸A3受體 (ADORA3)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Can-Fite BioPharma Ltd.
  • Huons Co., Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1354TDB

Summary:

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia.

It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 8, 4 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glaucoma, Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis, Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Irritable Bowel Syndrome, Kidney Fibrosis, Lupus Erythematosus, Melanoma, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Pulmonary Fibrosis.

The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
  • The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adenosine Receptor A3 (ADORA3) - Overview
    • Adenosine Receptor A3 (ADORA3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
    • Can-Fite BioPharma Ltd
  • Adenosine Receptor A3 (ADORA3) - Drug Profiles
    • ACN-1052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FM-1302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-1888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-2698 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • namodenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBF-1650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBF-677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adenosine Receptor A3 (ADORA3) - Dormant Products
  • Adenosine Receptor A3 (ADORA3) - Discontinued Products
  • Adenosine Receptor A3 (ADORA3) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
      • Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
      • Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities
      • Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
      • Jan 25, 2018: Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
      • Dec 18, 2017: Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
      • Nov 27, 2017: Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
      • Oct 30, 2017: Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis
      • Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
      • Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.
      • Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017
      • Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
      • Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
      • Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
      • Jul 17, 2017: Can-Fite's Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
Back to Top